vs
Side-by-side financial comparison of Insulet Corporation (PODD) and Primerica, Inc. (PRI). Click either name above to swap in a different company.
Primerica, Inc. is the larger business by last-quarter revenue ($853.7M vs $783.7M, roughly 1.1× Insulet Corporation). Primerica, Inc. runs the higher net margin — 23.1% vs 13.0%, a 10.1% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 11.0%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 7.2%).
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
Primerica, Inc. is a multi-level marketing company that provides insurance, investment and financial services to middle-income families in the United States and Canada.
PODD vs PRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $783.7M | $853.7M |
| Net Profit | $101.6M | $197.0M |
| Gross Margin | 72.6% | — |
| Operating Margin | 18.7% | 28.9% |
| Net Margin | 13.0% | 23.1% |
| Revenue YoY | 31.2% | 11.0% |
| Net Profit YoY | 0.9% | 17.9% |
| EPS (diluted) | $1.42 | $6.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $783.7M | $853.7M | ||
| Q3 25 | $706.3M | $839.9M | ||
| Q2 25 | $649.1M | $793.3M | ||
| Q1 25 | $569.0M | $804.8M | ||
| Q4 24 | $597.5M | $768.8M | ||
| Q3 24 | $543.9M | $774.1M | ||
| Q2 24 | $488.5M | $803.4M | ||
| Q1 24 | $441.7M | $742.8M |
| Q4 25 | $101.6M | $197.0M | ||
| Q3 25 | $87.6M | $206.8M | ||
| Q2 25 | $22.5M | $178.3M | ||
| Q1 25 | $35.4M | $169.1M | ||
| Q4 24 | $100.7M | $167.1M | ||
| Q3 24 | $77.5M | $164.4M | ||
| Q2 24 | $188.6M | $1.2M | ||
| Q1 24 | $51.5M | $137.9M |
| Q4 25 | 72.6% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 69.7% | — | ||
| Q1 25 | 71.9% | — | ||
| Q4 24 | 72.1% | — | ||
| Q3 24 | 69.3% | — | ||
| Q2 24 | 67.7% | 98.0% | ||
| Q1 24 | 69.5% | 98.2% |
| Q4 25 | 18.7% | 28.9% | ||
| Q3 25 | 16.7% | 32.3% | ||
| Q2 25 | 18.7% | 29.6% | ||
| Q1 25 | 15.6% | 27.5% | ||
| Q4 24 | 18.3% | 64.7% | ||
| Q3 24 | 16.2% | 32.9% | ||
| Q2 24 | 11.2% | 1.0% | ||
| Q1 24 | 12.9% | 24.1% |
| Q4 25 | 13.0% | 23.1% | ||
| Q3 25 | 12.4% | 24.6% | ||
| Q2 25 | 3.5% | 22.5% | ||
| Q1 25 | 6.2% | 21.0% | ||
| Q4 24 | 16.9% | 21.7% | ||
| Q3 24 | 14.2% | 21.2% | ||
| Q2 24 | 38.6% | 0.1% | ||
| Q1 24 | 11.7% | 18.6% |
| Q4 25 | $1.42 | $6.11 | ||
| Q3 25 | $1.24 | $6.35 | ||
| Q2 25 | $0.32 | $5.40 | ||
| Q1 25 | $0.50 | $5.05 | ||
| Q4 24 | $1.38 | $4.92 | ||
| Q3 24 | $1.08 | $4.83 | ||
| Q2 24 | $2.59 | $0.03 | ||
| Q1 24 | $0.73 | $3.93 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $756.2M |
| Total DebtLower is stronger | $930.8M | — |
| Stockholders' EquityBook value | $1.5B | $2.4B |
| Total Assets | $3.2B | $15.0B |
| Debt / EquityLower = less leverage | 0.61× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $756.2M | ||
| Q3 25 | — | $644.9M | ||
| Q2 25 | — | $621.2M | ||
| Q1 25 | — | $625.1M | ||
| Q4 24 | — | $687.8M | ||
| Q3 24 | — | $550.1M | ||
| Q2 24 | — | $627.3M | ||
| Q1 24 | — | $593.4M |
| Q4 25 | $930.8M | — | ||
| Q3 25 | $934.9M | — | ||
| Q2 25 | $939.0M | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $1.5B | $2.4B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.3B | $2.3B | ||
| Q4 24 | $1.2B | $2.3B | ||
| Q3 24 | $1.1B | $1.9B | ||
| Q2 24 | $998.4M | $2.1B | ||
| Q1 24 | $790.7M | $2.2B |
| Q4 25 | $3.2B | $15.0B | ||
| Q3 25 | $3.0B | $14.8B | ||
| Q2 25 | $3.5B | $14.8B | ||
| Q1 25 | $3.5B | $14.6B | ||
| Q4 24 | $3.1B | $14.6B | ||
| Q3 24 | $3.0B | $14.8B | ||
| Q2 24 | $2.9B | $14.6B | ||
| Q1 24 | $2.6B | $14.9B |
| Q4 25 | 0.61× | — | ||
| Q3 25 | 0.68× | — | ||
| Q2 25 | 0.64× | — | ||
| Q1 25 | 1.21× | — | ||
| Q4 24 | 1.07× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 1.36× | — | ||
| Q1 24 | 1.72× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $183.3M | $338.2M |
| Free Cash FlowOCF − Capex | $48.2M | — |
| FCF MarginFCF / Revenue | 6.2% | — |
| Capex IntensityCapex / Revenue | 17.2% | — |
| Cash ConversionOCF / Net Profit | 1.80× | 1.72× |
| TTM Free Cash FlowTrailing 4 quarters | $377.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $183.3M | $338.2M | ||
| Q3 25 | $125.7M | $202.9M | ||
| Q2 25 | $196.5M | $162.6M | ||
| Q1 25 | $63.8M | $197.5M | ||
| Q4 24 | $147.7M | $270.6M | ||
| Q3 24 | $98.5M | $207.3M | ||
| Q2 24 | $96.5M | $173.3M | ||
| Q1 24 | $87.6M | $210.9M |
| Q4 25 | $48.2M | — | ||
| Q3 25 | $100.1M | — | ||
| Q2 25 | $177.9M | — | ||
| Q1 25 | $51.5M | — | ||
| Q4 24 | $94.1M | — | ||
| Q3 24 | $71.8M | — | ||
| Q2 24 | $74.0M | — | ||
| Q1 24 | $65.5M | — |
| Q4 25 | 6.2% | — | ||
| Q3 25 | 14.2% | — | ||
| Q2 25 | 27.4% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 15.7% | — | ||
| Q3 24 | 13.2% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | 14.8% | — |
| Q4 25 | 17.2% | — | ||
| Q3 25 | 3.6% | — | ||
| Q2 25 | 2.9% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 4.6% | — | ||
| Q1 24 | 5.0% | — |
| Q4 25 | 1.80× | 1.72× | ||
| Q3 25 | 1.43× | 0.98× | ||
| Q2 25 | 8.73× | 0.91× | ||
| Q1 25 | 1.80× | 1.17× | ||
| Q4 24 | 1.47× | 1.62× | ||
| Q3 24 | 1.27× | 1.26× | ||
| Q2 24 | 0.51× | 147.98× | ||
| Q1 24 | 1.70× | 1.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
PRI
| Revenues From Sources Other Than Contracts With Customers | $445.9M | 52% |
| Investment And Savings Products Segment Revenues | $340.3M | 40% |
| Other | $56.5M | 7% |
| Segment Revenues From Contracts With Customers | $11.0M | 1% |
